LB Investment
VC Fund
Seoul, South Korea
LB Investment is a VC fund in Seoul focused on Health Care and Information Technology. LB Investment is one of the top VCs in Korea. LB invests in diverse industries ranging from Technology and Contents to Bio and healthcare
- Total investments:
- 175
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries LB Investment invests in
Stages LB Investment invests in
Countries LB Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $2.5M–$36M
- Series B
- $6.4M–$45M
- Series C
- $7.8M–$71M
Investment Focus
Industry
- Health Care 21 (12%)
- Information Technology 21 (12%)
- Artificial Intelligence 19 (11%)
- Software 17 (10%)
- E-Commerce 17 (10%)
Stage
- Series B 61 (35%)
- Series A 51 (29%)
- Series C 27 (15%)
- Venture - Series Unknown 11 (6%)
- Seed 7 (4%)
Country
- South Korea 103 (59%)
- United States 13 (7%)
- China 8 (5%)
- India 2 (1%)
- Russian Federation 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brian Boncheon Koo
CEO, Vice President
|
CEO, Vice President | Total investments: 0 | Find email | |
|
Dooseok Chae
Managing Director, Executive Director, and Head of Growth Secondary Headquarters
|
Managing Director, Executive Director, and Head of Growth Secondary Headquarters | Total investments: 1 | Find email | |
|
Hong Seok Jang
chief of LB Investment,
|
chief of LB Investment, | Total investments: 2 | Find email | |
|
Jeong Kyung-in
General manager
|
General manager | Total investments: 2 | Find email | |
|
Jung Hyeong-rok
Deputy general manager
|
Deputy general manager | Total investments: 1 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AD System focuses on the development, manufacturing, sales and repairing of drones and other unmanned aerial vehicles. | $9.4M / Series A / Sep 19, 2026 | ||
| ImpriMed is a company that creates individualized drug response prediction technology to help veterinarians fight lymphoma. The company's technology provides precision medicine techniques that allow veterinary oncologists to find appropriate anticancer drugs by developing a patient-derived database for pet cancer treatment that can eventuallybe translated into human cancer care, allowing doctors to decide on a final treatment regimen based on a data-driven prediction of response success in each individual patient's body. | $10M / Series A / Sep 18, 2026 | ||
| LINER is Asia’s first AI Agent that helps users accomplish more with less time and effort “AI Workspace”, known as the autonomous agent, performs various and complex tasks requested by users using LLM-based AI, differentiated by LINER’s highlighter database. More than 94% of LINER's users are from outside Korea & more than 100 countries.We are reducing our customer’s research time from hundreds of minutes to tens of seconds every day with our product. | $36.1M / Series C / Aug 25, 2026 | ||
| Point2 Technology develops a dielectric waveguide for high speed interconnect for both datacenter applications. The company is a provider of interconnect technology solutions that delivers ultra-low power, low-latency, point-to-point interconnect and range enhancement SoC solutions specifically designed to fulfill the bandwidth needs of hyperscaleAI/ML datacenters and 5G infrastructure. | $80M / Series B / Aug 10, 2026 | ||
| CarbonSix develops AI-powered robotics technologies for manufacturing automation, with a focus on tasks that involve high product variation and changing production conditions. Its platform uses imitation learning to enable industrial robots to learn from human demonstrations and perform complex manipulation tasks that are difficult to automateusing conventional programming methods. The company combines robotics hardware and AI software to improve robot adaptability while meeting industrial quality and reliability requirements. Its solutions are designed for manufacturing environments where flexible automation is needed for assembly and other variable production processes. | $40M / Series A / Jul 01, 2026 | ||
| The SMC Group is a social marketing company. | $13M / Jun 18, 2026 | ||
| Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $22.6M / Venture - Series Unknown / Jun 10, 2026 | ||
| XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing. | $135M / Series B / May 29, 2026 | ||
| Roai is a cutting-edge company that specializes in developing advanced autonomous manufacturing solutions powered by artificial intelligence and robotics. | $8.8M / Series A / Apr 30, 2026 | ||
| RXC is a startup that creates a differentiated next-gen media commerce platform that helps brands succeed. | $4.8M / Series A / Jan 07, 2026 | ||
| See all 175 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does LB Investment invest in?
LB Investment invests primarily in Health Care, Information Technology and Artificial Intelligence startups, most often at Series B and Series A stage. Most of the 175 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is LB Investment's check size?
LB Investment typically joins rounds of $2.5M–$36M at Series A, $6.4M–$45M at Series B and $7.8M–$71M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LB Investment participates in.
How do I contact LB Investment?
Public channels for LB Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LB Investment?
The team at LB Investment includes Brian Boncheon Koo (CEO, Vice President), Dooseok Chae (Managing Director, Executive Director, and Head of Growth Secondary Headquarters) and Hong Seok Jang (chief of LB Investment,), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
